Whereas the day 2 of the conference will be more focussed on cancer immunotherapies and personalised immunotherapies with presentations talking about Precision Immunology for targeted therapy, Biomarkers in Cancer Immunotherapy,
neoantigens in cancer immunotherapy, clinical development of ICI combinations and more.
As recognition of
neoantigens that result from somatic nonsynonymous mutations is associated with improved clinical responses to anti-PD-1 and anti-PD-L1 therapy, we hypothesized that patients with DM might respond well to anti-PD-1 or anti-PD-L1 therapies, owing to their high mutational load," Dr.
Neon Therapeutics, a clinical-stage immuno-oncology company developing
neoantigen-based therapeutics, is dedicated to transforming the treatment of cancer by directing the immune system towards
neoantigens.
NousCom's Exovax platform consists of viral vector-based genetic vaccines encoding cancer
neoantigens using proprietary prime / boost technology.
The company combined its vectored genetic vaccine encoding multiple cancer
neoantigens that are capable of inducing potent and broad T cell responses, with NKTR-214, developed to expand the specific population
This vaccine works by using multiple mutated proteins or
neoantigens that are specifically tied to an individual's tumor.
Moderna and Merck will develop personalized cancer vaccines that utilize Moderna's mRNA vaccine technology to encode a patient's specific
neoantigens, unique mutations present in that specific patient's tumor.
Indeed, in human lymphoblastoma-derived MCL-5 cells transfected with various human CYPs (hCYP), hCYP2B6 (and, to a lesser extent, hCYP2C8 and hCYP1A2) was able to catalyze the reaction of PERC to acetylated
neoantigens, which were recognized by immunoreactivity to anti-trifluoroacetylated antibodies (White et al.
Unlike previously tested cancer vaccinations that produced no concrete evidence of effectiveness, the injections targeted
neoantigens, specific proteins that are unique to each person's individual tumor.
Genomic analysis was performed and identified 578 potential mutation-associated
neoantigens in the MMR-defective groups (compared with only 21 in the MMR-proficient tumors).
Binding of formalin with endogenous proteins may result in formation of
neoantigens, which may elicit an immune response leading to various symptoms produced.
Moderna and Merck will develop personalized cancer vaccines that utilize Modernas mRNA vaccine technology to encode a patients specific
neoantigens, unique mutations present in that specific patients tumor.
